---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-058543"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T21:07:07.174579+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Acurx Pharma Q1 net loss $2.7M ($0.26/shr); Phase 2b CDI trial progressing

## Summary
- Cash $11.1M at March 31, 2022, down from $13.0M at Dec 31, 2021.
- Net loss $2.7M vs $1.5M YoY; R&D costs rose to $0.8M from $0.1M on Phase 2b trial costs.
- Phase 2b CDI trial enrollment ongoing; completion expected late H2 2022.
- Protocol amended to add exploratory Extended Clinical Cure endpoint at day 56 and day 84.
- Shares outstanding 10,263,202 as of March 31, 2022.

## SEC filing metadata
- accession: 0001104659-22-058543
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465922058543/0001104659-22-058543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465922058543/tm2214543d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-058543
- JSON: https://secwatch.observer/filing/0001104659-22-058543.json
- Plain text: https://secwatch.observer/filing/0001104659-22-058543.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.